Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders. The company’s marketed products include AMITIZA (lubiprostone), a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a potassium channel activator for the treatment of glaucoma and ocular hypertension. It has also filed a New Drug Application (sNDA) for AMITIZA in children 6 to 17 years of age with pediatric functional constipation (PFC). The company’s product candidate in clinical development stage is CPP-1X/sulindac combination product, which has completed Phase III clinical trial for the treatment of familial adenomatous polyposis. It is also developing VTS-270, which is in a Phase III trial for the treatment of Niemann-Pick Disease Type C1. The company operates in the United States, Japan, Switzerland, and internationally. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland. On August 28, 2023, Sucampo Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.